EJNMMI Research最新文献

{"title":"Measurement of specific and nonspecific tissue uptake of antibodies in tumor by SPECT imaging and nonlinear compartmental modeling.","authors":"Nicholas Cho, Jason Ho, Geoffrey Del Rosario, Shang-Fan Yu, Gregory Z Ferl, C Andrew Boswell","doi":"10.1186/s13550-025-01207-9","DOIUrl":"10.1186/s13550-025-01207-9","url":null,"abstract":"<p><strong>Background: </strong>Understanding the mechanisms driving specific and nonspecific tissue uptake of antibodies can inform protein engineering strategies that maximize therapeutic efficacy in target tissues while minimizing off-target tissue toxicities. While in vitro cell assays are typically used to study these internalization mechanisms, there are few methods readily available to evaluate these pathways in vivo. Single photon emission computed tomography (SPECT) imaging with a non-residualizing radiohalogen probe can measure total levels of intact antibody, and a residualizing radiometal-chelate probe, in combination with a non-residualizing probe, can measure catabolized antibody associated with receptor-mediated and nonspecific internalization processes. Here, we describe a SPECT imaging study in human epidermal growth factor receptor 2 (HER2)-expressing tumor-bearing mice aimed at measuring whole body disposition kinetics of tumor-targeting trastuzumab (anti-HER2) and non-targeting (anti-gD) antibodies. Mice received these molecules labeled with either a non-residualizing prosthetic group ([¹²⁵I]SIB) or with a residualizing radiometal-chelate (¹¹¹In-DOTA).</p><p><strong>Results: </strong>SPECT imaging data confirmed significant HER2-mediated tumor uptake and catabolism of anti-HER2, evidenced by the high ¹¹¹In-DOTA-anti-HER2 signal over time relative to ¹¹¹In-DOTA-anti-gD and the respective [¹²⁵I]SIB-labeled molecules. [¹²⁵I]SIB-anti-HER2 still showed noticeably higher tumor signal than [¹²⁵I]SIB-anti-gD, demonstrating a meaningful pool of intact anti-HER2 in the interstitial tumor compartment. Spleen showed the greatest catabolism of both mAbs amongst all non-tumor tissues. Compartmental modeling of the SPECT data demonstrated that cell-associated anti-HER2 was primarily receptor-bound, with a peak receptor occupancy of 35% at 13 h post administration of a 10 mg/kg dose, with minimal free and pinocytosed mAb.</p><p><strong>Conclusion: </strong>Here, we successfully developed an imaging and modeling approach to capture anti-HER2 antibody receptor binding as well as specific and nonspecific internalization over time in vivo. These data and analyses demonstrate the power of SPECT imaging using both non-residualizing and residualizing radioisotopes to better characterize the different biological states (free, bound, and catabolized) of antibodies within interstitial and intracellular compartments. Understanding these distinct antibody internalization mechanisms in tumor and non-tumor tissues enables more informed decisions on dose selection to optimize treatment of tumors with heterogeneous antigen expression while minimizing nonspecific toxicities.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"15 1","pages":"15"},"PeriodicalIF":3.1,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11850665/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143491281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of biocontainment on small animal PET performance adapted for BSL-2/3 infectious disease imaging research.","authors":"Isabella Salerno, Nadia Benabdallah, Amanda Fears, Ryan Unnerstall, Lindsey Hauck, Sergey Komarov, Linda Cox, Hanwen Zhang, Kevin Poenicke, Joseph Aromando, Yuan-Chun Tai, Timothy Wencewicz, Deborah J Veis, Daniel L J Thorek","doi":"10.1186/s13550-025-01202-0","DOIUrl":"10.1186/s13550-025-01202-0","url":null,"abstract":"<p><strong>Background: </strong>Biocontainment protocols are critical for conducting infectious disease (ID) research, particularly when using small animal models in biosafety level (BSL) 2/3 environments. This study evaluates the impact of poly-methyl methacrylate (PMMA) containment vessels on the performance of preclinical positron emission tomography (PET) systems. We tested containment vessels designed with varying wall thicknesses (3, 6, and 9 mm) to simulate ID imaging facility equipment and protocols. Through the use of multicomponent phantoms and in vivo mouse models of Staphylococcus aureus infection, we assessed key performance metrics including count rate, image quality, activity recovery, and spatial resolution.</p><p><strong>Results: </strong>The results indicate that the use of PMMA containment causes only minor reductions in imaging performance. The thickest PMMA (9 mm) led to a maximum 6.8% decrease in count rate, which remains well within the acceptable range of variation. Effects on spatial resolution were most noticeable for smaller structures within the phantom study, with a 19.65% difference in full width at half maximum (FWHM) for the thickest walled vessel. In vivo, using infected mice, the containment devices had modest effects on the task of activity concentration to be detected at the infection site, even with the thickest PMMA tube.</p><p><strong>Conclusion: </strong>These findings suggest that PMMA biocontainment vessels have small but measurable impact on preclinical PET system performance, making them a viable and cost-effective solution for conducting infectious disease imaging under BSL-2/3 conditions. Specifically, the thinnest containment (3 mm) had only minor effects on all tested parameters, suggesting it is well-suited for use in ID enclosures while maintaining accurate qualitative and quantitative assessments. This approach may reduce the burden for fully separate and specialized modifications for BSL-3 imaging facilities, and can be broadly applied to preclinical research involving pathogenic organisms.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"15 1","pages":"14"},"PeriodicalIF":3.1,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11845635/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143472397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unravelling physical and radiobiological effects of proton boron fusion reaction with anionic metallacarboranes ([o-COSAN]^-) in breast cancer cells.","authors":"Ana Belchior, Bianca C Alves, Edgar Mendes, Francisco Megre, Luís C Alves, Pedro Santos, Kai Nishimura, Hiroyuki Nakamura, Francesc Teixidor, Clara Viñas, Jorge Miguel Sampaio, Fernanda Marques, Teresa Pinheiro","doi":"10.1186/s13550-025-01199-6","DOIUrl":"10.1186/s13550-025-01199-6","url":null,"abstract":"<p><strong>Background: </strong>Protons, which are considered low-LET (Linear Energy Transfer) radiation, have an average RBE (relative biological effectiveness) of 1.1, with a range from 0.7 to 1.6. Thus, increasing biological effectiveness is of high interest in radiation oncology, and one way to enhance this is by using radiosensitizers. The present work investigates the effectiveness of the proton boron fusion reaction (PBFR) at the cellular level, using the sodium salt of metallacarborane [3,3'-Co(C2B9H11)2]^- (Na[o-COSAN]) as the boron source, aiming to explore the potential of this type of boron clusters as a radiosensitizer for proton therapy. Therefore, the main goal was to test the hypothesis that loading the cells with boron will favour the PBFR at energies close to the Bragg peak. This would enhance the radiation-induced biological effects through the production of alpha-particles.</p><p><strong>Results: </strong>MDA-MB-231 breast cancer cells were used. Nuclear microscopy assessed [o-COSAN] uptake and distribution in single cells, while biodistribution was studied in tumor-bearing Balb/cSlc-nu/nu mice (MDA-MB-231 xenograft), with boron accumulation in target organs and tumor measured by ICP-OES. The cells were irradiated with a proton beam tuned to reach the PBFR resonance energy of 675 keV at the cell layer. DNA damage was assessed with the g-H2AX assay and cell survival with the clonogenic assay. Beam parameters and dose calibration curves using radiochromic films validated Monte Carlo dosimetry simulations. As expected, we observed higher biological damage in irradiated cells and the presence of [o-COSAN]^- potentiated the damage. These results translate into a lower cellular viability, indicating that DNA damage imposed colonies smaller than their non-irradiated counterparts. This suggests that these damages either took longer time to be repaired or made the cells undergo less efficient survival mechanisms.</p><p><strong>Conclusions: </strong>The radiosensitizing effect of [o-COSAN]^- by strategic cellular ¹¹B placement and proton irradiation intensifies the DNA damage, making the nucleus particularly susceptible and thus increasing the destructive capability of alpha-particles, generated in the nuclear fusion reaction, which may lead to increased cell mortality.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"15 1","pages":"13"},"PeriodicalIF":3.1,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11845649/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143467373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First-in-human experience with GRPR antagonist [⁶⁸Ga]Ga-NOTA-PEG₂-RM26 in prostate and breast cancer patients using PET/CT.","authors":"Annie Bjäreback, Olof Jonmarker, Antonios Tzortzakakis, Emma Jussing, Chunde Li, Renske Altena, Cecilia Hindorf, Anna Orlova, Rimma Axelsson, Thuy A Tran","doi":"10.1186/s13550-025-01204-y","DOIUrl":"10.1186/s13550-025-01204-y","url":null,"abstract":"","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"15 1","pages":"12"},"PeriodicalIF":3.1,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11842642/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143457302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic and prognostic role of ¹⁸F-FDG PET/CT for sarcomatoid differentiation in renal cell carcinoma.","authors":"Ritai Na, Zhao Chen, Yongshun Liu, Qianrui Chen, Qi Yang, Yongkang Qiu, Tianyao Wang, Lele Song, Sitong Wu, Wenpeng Huang, Xinyao Sun, Shaozhong Xian, Lei Kang","doi":"10.1186/s13550-025-01206-w","DOIUrl":"10.1186/s13550-025-01206-w","url":null,"abstract":"<p><strong>Background: </strong>Sarcomatoid differentiation is an invasive dedifferentiated feature of tumor and associated with poor prognosis in renal cell carcinoma (RCC) patients. This study aimed to evaluate the utility of ¹⁸F-FDG PET/CT in predicting sarcomatoid differentiation in RCC and its potential prognostic value.</p><p><strong>Results: </strong>This retrospective study assessed newly diagnosed sarcomatoid differentiation renal cell carcinoma (SDRCC) patients who were staged using ¹⁸F-FDG PET/CT. Patients were categorized into high-grade sarcomatoid differentiation RCC (HG-SDRCC), low-grade sarcomatoid differentiation RCC (LG-SDRCC), and non-sarcomatoid differentiation RCC (non-SDRCC). The maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were compared. Overall survival (OS) and disease-free survival (DFS) were analyzed. SUVmax, MTV, TLG, and SUVmean values were significantly higher in SDRCC compared to non-SDRCC (P < 0.05). Additionally, SUVmax, TLG, and SUVmean were significantly higher in HG-SDRCC compared to non-HG-SDRCC (P < 0.05). ROC curves revealed that SUVmax and SUVmean were effective for distinguishing HG-SDRCC from non-HG-SDRCC. The log-rank test identified SUVmax > 11, MTV > 95, TLG > 500, SUVmean > 5.2, invasion of peripheral tissue and/or organs, and metastasis as risk factors for SDRCC patients. Multivariate Cox proportional hazards model analyses indicated that TLG > 500 was a risk factor for poor DFS, while SUVmax > 11 and SUVmean > 5.2 were risk factors for poor OS.</p><p><strong>Conclusions: </strong>¹⁸F-FDG PET/CT can effectively differentiate HG-SDRCC with more aggressive malignancy. The prognostic model developed in this study demonstrates that metabolic parameters, particularly TLG for DFS and SUVmax/SUVmean for OS, serve as more robust predictors of patient outcomes than the degree of sarcomatoid differentiation.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"15 1","pages":"11"},"PeriodicalIF":3.1,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11839549/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143457296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CXCR4-targeted PET imaging in rheumatoid arthritis: a novel approach for monitoring disease activity and therapeutic response.","authors":"Ya Han, Shuo Cao, Jie Liu, Binbin Ding, Shijie Wang, Jihong Pan, Yongpeng Ge, Kai Cheng, Lin Wang, Luna Ge","doi":"10.1186/s13550-025-01203-z","DOIUrl":"10.1186/s13550-025-01203-z","url":null,"abstract":"<p><strong>Background: </strong>Rheumatoid arthritis (RA) is a common chronic, inflammatory autoimmune disease, and early clinical diagnosis is crucial for its treatment. CXCR4 expression was characterized in arthritic mouse models and joints of RA patients, and [¹⁸ F]AIF-NOTA-QHA-04 specificity was assessed in non-malignant cells with elevated CXCR4 expression. This study explored the application of CXCR4-targeted PET probe [¹⁸ F]AIF-NOTA-QHA-04 in monitoring disease activity and therapeutic efficacy in RA. To this aim, the metabolic characteristics of [¹⁸ F]AIF-NOTA-QHA-04 and correlation of [¹⁸ F]AIF-NOTA-QHA-04 uptake with arthritis severity were evaluated by PET imaging in arthritic mice. [¹⁸ F]AIF-NOTA-QHA-04 potential in evaluating therapeutic efficacy was further investigated in arthritic mice following methotrexate (MTX) and etanercept (ETC) treatment.</p><p><strong>Results: </strong>CXCR4 expression was significantly increased in the inflamed joints of collagen-induced arthritis (CIA) and collagen-antibody induced arthritic (CAIA) mice, and in synovial tissues of RA patients. [¹⁸ F]AIF-NOTA-QHA-04 showed high specificity for CXCR4, with increased probe uptake in arthritic joints that was strongly correlated with arthritis severity scores. PET imaging revealed that increased uptake of [¹⁸ F]AIF-NOTA-QHA-04 in arthritic joints paralleled disease activity, with uptake decreasing upon remission. Furthermore, [¹⁸ F]AIF-NOTA-QHA-04 PET imaging provided earlier and more sensitive assessments of the efficacy of MTX and ETC compared to traditional methods.</p><p><strong>Conclusion: </strong>The CXCR4-targeted PET probe [¹⁸ F]AIF-NOTA-QHA-04 is a promising tool for RA diagnosis and monitoring, with high specificity and sensitivity. The potential of this probe as a biomarker for disease activity and therapeutic response underscores its value in personalized medication strategies for the management of RA.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"15 1","pages":"10"},"PeriodicalIF":3.1,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11836264/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143448550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quantification in respiratory-gated PET acquisition: can data-driven methods replace device-based systems?-a comparative and retrospective study.","authors":"Laurentiu Agrigoroaie, Nadege Anizan, Camilo Garcia, Corinne Balleyguier, Théophraste Henry","doi":"10.1186/s13550-025-01195-w","DOIUrl":"10.1186/s13550-025-01195-w","url":null,"abstract":"<p><strong>Background: </strong>Device-based respiratory gating improves diagnostic and quantification accuracy in positron emission tomography (PET), but requires additional time to setup the device and the failure rate can be significant. Our aim was to internally validate the quantification performance of data-driven respiratory-gated PET imaging against the gold standard, the device-based method, in clinical oncological practice. We retrospectively analysed [18F]FDG PET/CT scans of patients from our centre with at least one measurable [18F]FDG-avid malignant lesion. All PET/CT acquisitions were performed on a Siemens Biograph 64 Vision 600 system with respiratory gating by belt and also by adding the data-driven gating with OncoFreeze AI™. We recorded the SUVmax and SUVpeak for up to a maximum of 5 lesions per patient. We computed the mean absolute bias between the two gating methods and the 95% confidence intervals (CI) at the cohort level and in subgroups.</p><p><strong>Results: </strong>Of the 692 consecutive patients screened for inclusion, 196 patients were analysed, from whom 536 lesions were measured. The mean absolute biases in the SUVmax and SUVpeak of lesions in the whole cohort were 3.8% (CI 3.4-4.2) and 2.1% (CI 1.9-2.4), respectively. At patient-level, 21% of them had at least one lesion with a SUVmax bias above 10%, while for SUVpeak this proportion was 5%. In the subgroup analysis by PERCIST criteria, only 2% of patients had significant bias in the SUVmax, and 0.5% in SUVpeak. There was no clinically significant effect of lesion size or anatomical site on SUV measurements between the two respiratory gating methods.</p><p><strong>Conclusion: </strong>Quantitative comparison of data-driven and device-based respiratory-gated PET scans revealed negligible differences, proving that data-driven respiratory gating is a reliable and accurate alternative to the device-based gating method in routine [18F]FDG-PET/CT oncological evaluation.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"15 1","pages":"9"},"PeriodicalIF":3.1,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11828764/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Venous blood sampling for less invasive in vivo quantification of synaptic density with constant infusion of [¹⁸F]SynVesT-1 and PET.","authors":"Ruth H Asch, Mika Naganawa, Karina Moisieienko, Mia Weed, Michael Kapinos, Ming-Qiang Zheng, Ansel T Hillmer, Richard E Carson, Robert H Pietrzak, Irina Esterlis","doi":"10.1186/s13550-025-01200-2","DOIUrl":"10.1186/s13550-025-01200-2","url":null,"abstract":"","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"15 1","pages":"8"},"PeriodicalIF":3.1,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11790547/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143122542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Value of multi-parameter ¹²³I-MIBG scintigraphy in the differential diagnosis of Parkinson's disease.","authors":"Teng Xue, Ying Cui, Ying Kan, Guanyun Wang, Jigang Yang","doi":"10.1186/s13550-025-01197-8","DOIUrl":"10.1186/s13550-025-01197-8","url":null,"abstract":"<p><strong>Background: </strong>¹²³I-MIBG scintigraphy plays a significant role in diagnosing Parkinson's disease (PD), with most studies primarily targeting cardiac uptake and relying on traditional ratio-based parameters for assessment. However, due to variations in scanning conditions and image processing methodologies, the clinical utility of different parameters remains a subject of debate. This study aims to evaluate the diagnostic accuracy of multi-parameter ¹²³I-3-Iodobenzylguanidine (MIBG) scintigraphy and to identify the most reliable metrics for distinguishing PD from Parkinson-plus syndromes.</p><p><strong>Result: </strong>We recruited 56 PD patients and 44 non-PD controls, who underwent ¹²³I-MIBG scintigraphy and clinical evaluation. MIBG uptake and washout rates (WR) for the heart, salivary glands, and thyroid were assessed, with semi-quantitative methods used to calculate heart-to-mediastinum (H/M) and gland-to-background (P/B, S/B, T/B) ratios. Diagnostic efficacy was evaluated using receiver operating characteristic (ROC) curves. The H/M ratio and cardiac WR parameters scintigraphy exhibited excellent diagnostic efficacy for PD and PPS. The 4 h H/M ratio showed superior diagnostic performance with an area under the ROC curve (AUC) of 0.980. Background and time decay correction improved cardiac WR diagnostic performance (AUC = 0.963). Although P/B, S/B, and T/B ratios showed no significant differences for differential diagnosis, the WR values of the parotid and thyroid glands exhibited moderate diagnostic efficacy with AUCs of 0.648 and 0.638, respectively.</p><p><strong>Conclusion: </strong>The heart H/M ratio and cardiac WR in ¹²³I-MIBG scintigraphy show high diagnostic efficacy for both diagnosing and differentiating PD. Including cardiac WR in routine assessments is recommended. The diagnostic potential of WR in the parotid and thyroid glands also holds promise for PD diagnosis. Incorporating these parameters could enhance the accuracy of PD diagnosis, particularly in clinical scenarios where concurrent cardiac disease may confound the diagnosis.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"15 1","pages":"7"},"PeriodicalIF":3.1,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11775374/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143058512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"⁶⁸Ga-NOTA-RM26 PET/CT in the evaluation of glioma: a pilot prospective study.","authors":"Yilin Li, Rongxi Wang, Jingci Chen, Zhaohui Zhu, Yu Wang, Wenbin Ma","doi":"10.1186/s13550-025-01198-7","DOIUrl":"10.1186/s13550-025-01198-7","url":null,"abstract":"<p><strong>Background: </strong>Gliomas are the most common malignant primary tumors of the central nervous system. There is an urgent need for new convenient, targeted and specific imaging agents for gliomas. This study aimed to firstly evaluate the feasibility of ⁶⁸Ga-NOTA-RM26 PET/CT imaging in glioma and analyze the relationship between the imaging characteristics and glioma grade, classification and molecular alterations.</p><p><strong>Results: </strong>Twenty-two patients were confirmed as glioma by surgery or biopsy. All patients exhibited ⁶⁸Ga-NOTA-RM26 uptake. SUV_max was chosen as the imaging marker for analysis. For all glioma patients, there were significant differences between grades (P = 0.047). For primary gliomas, SUV_max had good discrimination for both tumor classifications (P = 0.045) and grades (P = 0.03). There was a positive correlation (P < 0.01) between GRPR expression level and SUV_max. P53 mutations caused significant differences in SUV_max (P = 0.03).</p><p><strong>Conclusions: </strong>This study is the first application of ⁶⁸Ga-NOTA-RM26 in glioma patients and confirmed the safety and efficacy in glioma patients. ⁶⁸Ga-NOTA-RM26 PET/CT has potential value in tumor grade, classification, and molecular alterations.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov: NCT06412952. Registered 26 April 2024, https://clinicaltrials.gov/study/NCT06412952.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"15 1","pages":"6"},"PeriodicalIF":3.1,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11748694/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143002217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}